Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Discoveries Show Early Promise for Opioid Addiction Treatment

By Ryan Bushey | August 22, 2016

The opioid epidemic sweeping the country is becoming a difficult problem to solve. Two years ago, the U.S. experienced the most drug overdoses on record with a majority involving opioids, according to the Department of Health and Human Services.

One reason for this is that some experts believe there’s been a considerable uptick in prescribing painkillers where the strength of these drugs can force people to turn to heroin or similar illicit compounds to compensate when they run out. Politicians and lawmakers have discussed establishing plans to fight lax prescription standards or investing in more drug treatment and mental health services.

However, last week brought an intriguing bit of news regarding drugs that could combat this problem.  

First, Indivior announced its candidate for combatting opioid dependence reached its primary endpoint and a key secondary outcome, reported FierceBiotech. The drug, RBP-6000, is a slow-release injection of buprenorphine that needs to be taken every month.

The Phase 3 study featured 489 patients with moderate to severe opioid disorder who sought medication to manage their conditions. Investigators initially gave patients a variant of buprenorphine called Suboxone, but then randomly gave the treatment groups either placebo or low or high doses of RBP-6000.

Testing lasted for 24 weeks in which Indivior asked patients about their opioid use and analyzed urine samples to find traces of the drug.

The primary study endpoint was reached when the company learned both treatment arms, “outperformed placebo against the combined urine sample,” according to FierceBiotech. A secondary outcome was reached when the investigators noticed the collected urine samples tested negative for opioids at least 80 percent of the time.

Also, a group of academic researchers announced they had developed safe opioid that could be a safer alternative to morphine.

A team of scientists from Stanford University, UC San Francisco, University of North Carolina, and Friedrich Alexander University, designed a novel compound, PZM21, that has the same potency as morphine but doesn’t have the ability to cause respiratory suppression.

The drug was tested in a group of mice where the creatures had demonstrated early signs of not succumbing to addiction with this drug. Still, there needs to be more research done on other animal subjects in order to determine this compound’s potency.

All of this could bode well. Indivior already has a fast-track designation for RBP-6000, but the positive results can help bolster its quest to get regulatory approval while the characteristics of PZM61 would provide relief for authorities, family members, and patients concerned about this growing issue.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE